Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech ...( SHANGHAI China March 31 /Xinhua--...),Health

SHANGHAI, China, March 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech, the leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, was very honored to have Professor David W. C. MacMillan, a renowned researcher from Princeton University, as a WuXi PharmaTech Science Seminar Series speaker who delivered a lecture to the company's young scientists on March 25, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Aiming to keep the company's young scientists abreast of the latest drug R&D knowledge and technologies, the WuXi PharmaTech Science Seminar Series is a monthly program that invites accomplished researchers from academia and the industry to share their wealth of experience and expertise with the company's scientists.

Dr. David MacMillan obtained his undergraduate degree from Glasgow University, and in 1990 moved to the University of California, Irvine, where he obtained his Ph.D. under the direction of Larry E. Overman. Following postdoctoral research with David A. Evans at Harvard University, Dr. MacMillan began his independent research career at the University of California, Berkeley, in 1998. In 2000, he joined the department of chemistry at Caltech, and was promoted to full professor in 2003. He was appointed to the A. Barton Hepbum Chair of Chemistry and Director of the Merck Center for Catalysis at Princeton University in June 2006.

Dr. MacMillan is a leader in the currently active area of asymmetric organocatalysis. His numerous accomplishments have found widespread industrial application and his success is evidenced by the numerous awards and honors he has received from professional associations like the Royal Society of Chemistry, the American Chemical Society and the industry.

"We are very honored and privileged to have Dr. MacMillan as one o
'/>"/>